Boston Scientific vs Cencora

Boston Scientific (BSX), health care, and Cencora (COR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Cencora is worth $67.5B on the stock market and Boston Scientific $62.6B: Cencora is valued at 8% more. Boston Scientific trades at 18.2 times earnings and Cencora at 19.7; operating margins in their latest fiscal years were 18.0% and 0.82%. Over the past year Boston Scientific's share price has moved -56.0% and Cencora's -1.30%.

Key facts

Boston Scientific market value
$62.6B
Cencora market value
$67.5B
Boston Scientific P/E
18.2
Cencora P/E
19.7
Boston Scientific revenue
$20.1BFY to 2025-12-31
Cencora revenue
$321.3BFY to 2025-09-30
Superinvestors holding both
1

Market values as of .

Boston Scientific vs Cencora: every measure side by side
Measure Boston Scientific Cencora
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-09-30
Size
Market cap$62.6Blower$67.5Bhigher
Revenue$20.1Blower$321.3Bhigher
Earnings$2.9Bhigher$1.6Blower
Employees59,000—
Total assets$43.7Blower$76.6Bhigher
Valuation
P/E18.2lower19.7higher
P/S3.1higher0.2lower
P/B2.4lower18.3higher
Dividend yield0.00%lower0.67%higher
Profitability
Operating margin18.0%higher0.82%lower
Balance sheet
Net assets$24.2Bhigher$1.5Blower
Total liabilities$19.2Blower$74.8Bhigher
Total debt$11.4Bhigher$7.7Blower
Cash on hand$2Blower$4.4Bhigher
Price change
Today-1.09%lower-0.95%higher
1 year-56.0%lower-1.30%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Boston Scientific / Cencora). Who owns BSX · Who owns COR

Further comparisons

Learn

Questions and answers

Which is bigger, Boston Scientific or Cencora?

By market value, Cencora is the larger: $67.5B against $62.6B for Boston Scientific. By revenue in its latest fiscal year, Cencora is the larger: $321.3B against $20.1B for Boston Scientific.

Which has the higher P/E ratio?

Cencora: 19.7, against 18.2 for Boston Scientific. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Boston Scientific: 18.0%, against 0.82% for Cencora. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Cencora: 0.67%, against 0.00% for Boston Scientific. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Boston Scientific: $11.4B, against $7.7B for Cencora. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Boston Scientific and Cencora?

In their latest 13F filings, Israel Englander holds both.

Cite this page

Funkfolio, “Boston Scientific vs Cencora”, data as of 17 November 2026. https://funkfolio.com/compare/bsx-vs-cor

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.